RT Journal Article
T1 DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.
A1 Hidalgo-Tenorio, Carmen
A1 Vinuesa, David
A1 Plata, Antonio
A1 Martin-Davila, Pilar
A1 Iftimie, Simona
A1 Sequera, Sergio
A1 Loeches, Belen
A1 Lopez-Cortes, Luis Eduardo
A1 Fariñas, Mari Carmen
A1 Fernandez-Roldan, Concepcion
A1 Javier-Martinez, Rosario
A1 Muñoz, Patricia
A1 Arenas-Miras, Maria Del Mar
A1 Martinez-Marcos, Francisco Javier
A1 Miro, Jose Maria
A1 Herrero, Carmen
A1 Bereciartua, Elena
A1 De-Jesus, Samantha E
A1 Pasquau, Juan
K1 Bloodstream infection
K1 Dalbavancin
K1 Endocarditis
AB To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20€) and 557 days for IE (283,187.45€). DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug.
PB BioMed Central
YR 2019
FD 2019-10-19
LK http://hdl.handle.net/10668/15000
UL http://hdl.handle.net/10668/15000
LA en
NO Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Dávila P, Iftimie S, Sequera S, et al. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob. 2019 Oct 19;18(1):30
DS RISalud
RD Apr 9, 2025